DeepLife
Elie Hatem, Ph.D., currently serves as the Head of Products & Strategic Programs at DeepLife, overseeing product strategy, development, and program management while promoting cross-functional collaboration and mentoring. Previously, Elie held roles at Sebia, where responsibilities included agile project management for new markers and AI solutions, as well as serving as a scientific advisor. Prior experience includes leadership in R&D project development at Genopole and Institut Curie, focusing on drug repurposing and biomarker projects. Academic qualifications include a Ph.D. in Biochemistry and Molecular Biology from UVSQ, along with entrepreneurial and project management training from institutions such as HEC Paris and INSEAD.
This person is not in any teams
DeepLife
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.